Abstract
Donor qualification assessment is a critical step in ensuring the safety and efficacy of the hematopoietic progenitor cell (HPC) transplantation process. Donor qualification refers to aspects of the donor that may affect safety of the donor, safety of the recipient, and success of the HPC transplantation in the recipient. This definition is synonymous with the term “donor suitability” used by the World Marrow Donor Association (WMDA) and American Association of Blood Banks (AABB). However, the term donor qualification is used for clarity because the term donor suitability can have different connotations in various contexts. For example, in FACT accreditation parlance, donor suitability is defined more narrowly as issues “that relate to the general health or medical fitness of the donor to undergo the collection procedure.” In FDA parlance, in contrast, “donor suitability” is used interchangeably with “donor eligibility” or the infectious disease risk of the donor to recipient safety. The chapter provides an overview of the most important concepts in donor qualification assessment and a practical framework of how to systematically evaluate donor qualification.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Society of Anesthesiologists (2014) ASA physical status classification system
Babushok DV, Bessler M, Olson TS (2016) Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Leuk Lymphoma 57(3):520–536
Bitan M et al (2016) Determination of eligibility in related pediatric hematopoietic cell donors: ethical and clinical considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. Biol Blood Marrow Transplant 22(1):96–103
Burns LJ et al (2016) Recovery of unrelated donors of peripheral blood stem cells versus recovery of unrelated donors of bone marrow: a prespecified analysis from the phase III blood and marrow transplant clinical trials network protocol 0201. Biol Blood Marrow Transplant 22(6):1108–1116
Churpek JE et al (2012) Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood 120(26):5247–5249
Fleisher LA et al (2014) 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 64(22):e77–137
Hackett NJ, De Oliveira GS, Jain UK, Kim JY (2015) ASA class is a reliable independent predictor of medical complications and mortality following surgery. Int J Surg 18:184–190
Halter J et al (2009) Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 94(1):94–101
Halter JP et al (2013) Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transplant 48(2):220–225
Kang EM et al (2002) Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 99(3):850–855
Kristensen SD et al (2014) 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 35(35):2383–2431
Kroschinsky F et al (2004) Severe autoimmune hyperthyroidism after donation of growth factor-primed allogeneic peripheral blood progenitor cells. Haematologica 89(4):ECR05
Lee JB et al (2016) Exacerbation of IgA nephropathy following G-CSF administration for PBSC collection: suggestions for better donor screening. Bone Marrow Transplant 51(2):286–287
Lown RN et al (2014) Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee. Bone Marrow Transplant 49(7):880–886
Panch SR et al (2016) Hematopoietic progenitor cell mobilization is more robust in healthy African American compared to Caucasian donors and is not affected by the presence of sickle cell trait. Transfusion 56(5):1058–1065
Parkkali T, Volin L, Siren MK, Ruutu T (1996) Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. Bone Marrow Transplant 17(3):433–434
Pulsipher MA et al (2013) Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood 121(1):197–206
Pulsipher MA et al (2014) Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood 123(23):3655–3663
Snowden JA et al (2012) Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 47(6):770–790
Spitzer T, McAfee S, Poliquin C, Colby C (1998) Acute gouty arthritis following recombinant human granulocyte colony-stimulating factor therapy in an allogeneic blood stem cell donor. Bone Marrow Transplant 21(9):966–967
Tsuchiyama J et al (2000) Recurrent idiopathic iridocyclitis after autologous peripheral blood stem-cell transplantation followed by G-CSF administration for acute lymphoblastic leukemia. Ann Hematol 79(5):269–271
van Walraven SM et al (2010) Family donor care management: principles and recommendations. Bone Marrow Transplant 45(8):1269–1273
Worel N et al (2015) Suitability criteria for adult related donors: a consensus statement from the worldwide network for blood and marrow transplantation standing committee on donor issues. Biol Blood Marrow Transplant 21(12):2052–2060
World Marrow Donor Association Clinical Working Group C (2016) WMDA donor medical suitability recommendations
Xiao H et al (2011) First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood 117(19):5257–5260
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Shi, P. (2018). Donor Qualification for Hematopoietic Cell Transplantation. In: Schwartz, J., Shaz, B. (eds) Best Practices in Processing and Storage for Hematopoietic Cell Transplantation . Advances and Controversies in Hematopoietic Transplantation and Cell Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-58949-7_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-58949-7_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-58948-0
Online ISBN: 978-3-319-58949-7
eBook Packages: MedicineMedicine (R0)